Journal of Clinical Oncology
Articles in this Issue
Current patterns of care: Referral to palliative care for patients with metastatic gynecologic cancer.
12089 Background: Multiple professional cancer organizations have clinical guidelines that recommend that patients with advanced cancers be referred to pa...
Characterization of tumor immune microenvironment in gastric cancer patients with peritoneal metastasis.
e16054 Background: Immunotherapy combined with chemotherapy is the standard palliative systemic treatment for locally advanced unresectable or metastatic...
Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).
4020 Background: In previously treated patients (pts) with advanced extra-pancreatic NET (epNET) or pancreatic NET (pNET), cabozantinib (cabo) demonstrate...
Comparative efficacy and safety of novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A systematic review and Bayesian network meta-analysis.
e17042 Background: Nonmetastatic castration-resistant prostate cancer (nmCRPC) progresses despite androgen deprivation therapy (ADT), necessitating additi...
Neoadjuvant toripalimab plus CapeOX in patients with locally advanced EBV-positive gastric or esophagogastric junction adenocarcinoma (GC/EGJC): Results from the phase II NICE trial.
4069 Background: Surgery remains the cornerstone of curative therapy for locally advanced GC/EGJC. EBV-positive tumor is a distinct molecular subtype that...
Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.
e16111 Background: The long-term survival data for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy a...
Analysis of BAI3 as a potential biomarker for lung cancer immunotherapy.
e20556 Background: Brain angiogenesis inhibitor protein 3 (BAI3/ADGRB) belongs to the family of adhesion G protein-coupled receptors (GPCRs). Recently, em...
Challenges in knowledge graph generation for breast cancer using open-source LLMs and the role of mCODE.
e13704 Background: Generative AI has demonstrated potential for structuring electronic health record data, extracting meaningful insights, and mapping tre...
Germline non- <i>BRCA1/2</i> mutations and clinico-radio-pathologic features of early-onset breast cancer patients in Thailand.
e22594 Background: BRCA1/2 mutations account for the majority of early-onset breast cancer (BC); however, nearly half of pathogenic/likely pat...
Survival with <i>EGFR</i> , <i>HER2</i> alterations in aUC: A multi-institution, real-world cohort.
e16552 Background: Although overexpression of EGFR occurs in up to 74% of advanced urothelial carcinoma (aUC), alterations are rar...
A phase III randomized controlled trial comparing palliative stereotactic body radiotherapy vs. palliative standard radiotherapy in patients with advanced head and neck cancer (NCT06641791).
TPS6118 Background: The optimal radiotherapy (RT) treatment regimen for patients with advanced head and neck cancer (AHNC) unsuitable to receive curative...
Impact of perioperative complications on ctDNA-based MRD detection and prognosis: Insights from the GALAXY study.
3600 Background: The GALAXY study (UMIN000039205) demonstrated the utility of circulating tumor DNA (ctDNA)testing to detect molecular residual disease (M...
Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review.
8584 Background: The optimal duration of immune checkpoint inhibitor (ICI) therapy in advanced or metastatic non-small cell lung cancer (NSCLC) is unknown...
Immune profiling to identify a functionally high-risk smoldering multiple myeloma patient population.
7534 Background: Smoldering multiple myeloma (SMM), a precursor to active multiple myeloma (MM), is characterized by a high plasma cell burden but no evid...
Do all patients with primary retroperitoneal sarcoma benefit from resection?
e23549 Background: We aimed to determine the impact of early recurrence on the prognosis of patients who have undergone resection of primary retroperitone...
A phase Il trial to assess the impact of β2 adrenergic receptor (β2-AR) blockade in metastatic triple negative breast cancer (mTNBC).
TPS1140 Background: In PD-L1+ mTNBC patients (pts), the standard of care treatment is chemotherapy and pembrolizumab (P) in the first-line setting. Our gr...
Longitudinal tumor-informed cfDNA whole genome sequencing to capture residual disease during neoadjuvant immune checkpoint inhibition in resectable gastroesophageal cancer.
2550 Background: Although circulating tumor DNA (ctDNA) detection represents a promising approach to capture minimal residual disease (MRD), the clinical...
Genetic profile of low-grade diffuse glioma in patients followed at the National Cancer Institute between 2009 and 2015.
e14020 Background: In Brazil, approximately 11,490 new cases of malignant Central Nervous System (CNS) tumors are expected between 2023 and 2025. Historic...
Single center study of efficacy and safety of capivasertib in hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC).
e13101 Background: Capivasertib and alpelisib have shown efficacy in clinical trials of HR+/HER2- MBC when used in patients (pts) with PI3K pathway altera...
Opinions of real-world clinicians regarding visceral crisis in HR+/HER2- mBC: Results from the RETRACT survey of US oncologists.
e13081 Background: In approximately 10-15% of HR+/HER2- advanced breast cancer cases, the onset or progression of disease is sudden and accompanied by a r...
Dynamic hematological indicators as predictors of CDK4/6 inhibitors efficacy in HR-positive, HER2-negative metastatic breast cancer.
e13075 Background: Birociclib, a novel CDK4/6 inhibitor, has been evaluated in the BRIGHT-2 study, a phase 3 randomized controlled trial (RCT), to assess...
Eosinophilia and basophilia in essential thrombocythemia and polycythemia vera: Clinical, genetic, and prognostic correlates.
e18600 Background: Recent studies have suggested that basophilia in myeloproliferative neoplasms (MPN), in general, and in primary myelofibrosis (PMF), in...
Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC).
3534 Background: Acquired resistance limits the efficacy of anti-EGFR (EGFRi) therapy in RAS wild-type (WT) mCRC, often through MAPK reactivation driven b...
The impact of dietary patterns on inflammation and colon cancer risk: A retrospective study of 796 patients.
3618 Background: Colon cancer significantly contributes to global cancer rates, with rising incidence linked to dietary and lifestyle changes. Diets high...
Association of a novel RNA m6A regulatory gene expression signature with proliferation and disease progression in oral cancer.
e18060 Background: This study investigated the expression patterns and clinical importance of a newly identified RNA m6A regulatory gene, CNBP, in oral sq...